We are live on ! Find out more
VVM

Versant Venture Management Portfolio holdings

AUM $141M
1-Year Est. Return 190.82%
This Fund
S&P 500
This Quarter Est. Return
-14.61%
1 Year Est. Return
+190.82%
3 Year Est. Return
+375.7%
5 Year Est. Return
+81.85%
10 Year Est. Return
+4,735.29%
AUM
$294M
AUM Growth
-$26.5M
Cap. Flow
+$40.3M
Cap. Flow %
13.72%
Top 10 Hldgs %
100%
Holding
10
New
1
Increased
1
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
VCYT icon
Veracyte
VCYT
+$39.9M
2
CBAY
Cymabay Therapeutics
CBAY
+$448K

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 95.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRSP icon
1
CRISPR Therapeutics
CRSP
$4.68B
$160M 54.44%
3,608,874
– –
BOLD
2
DELISTED
Audentes Therapeutics, Inc
BOLD
$47.7M 16.22%
1,204,615
– –
VCYT icon
3
Veracyte
VCYT
$4.44B
$34.5M 11.75%
+3,616,221
New +$39.9M
OCUL icon
4
Ocular Therapeutix
OCUL
$1.85B
$15.2M 5.18%
2,215,384
– –
CBAY
5
DELISTED
Cymabay Therapeutics
CBAY
$12M 4.09%
1,084,696
+36,095
+3% +$448K
VANI icon
6
Vivani Medical
VANI
$113M
$8.54M 2.9%
187,207
– –
IMDZ
7
DELISTED
Immune Design Corp.
IMDZ
$7.62M 2.59%
2,208,210
– –
AKAO
8
DELISTED
Achaogen Inc
AKAO
$5.11M 1.74%
1,281,152
– –
CLVS
9
DELISTED
Clovis Oncology, Inc.
CLVS
$2.99M 1.02%
101,855
– –
OPGN
10
DELISTED
OpGen, Inc
OPGN
$207K 0.07%
26
– –

Similar funds

POIA
Pin Oak Investment Advisors Houston, Texas $141M AUM 20.83% 1-Year Est. Return
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
TM
TFJ Management Somerville, Massachusetts $141M AUM 9.28% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
RB
Renasant Bank Tupelo, Mississippi $141M AUM 16.9% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
CFGW
Chancellor Financial Group WB Wilkes-Barre, Pennsylvania $141M AUM 23.22% 1-Year Est. Return

Versant Venture Management's Q3 2018 Portfolio in Review

As of Q3 2018, Versant Venture Management held 10 positions worth $294M, down 8.3% from $321M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Versant Venture Management deployed $40.3M of net new capital in Q3 2018, opening 1 new position and adding to 1 existing holding. Its largest new stake was Veracyte: 3,616,221 shares worth $34.5M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 93% a quarter earlier.

  • Versant Venture Management's largest Q3 2018 buy was Veracyte: 3,616,221 shares worth $34.5M.
  • Versant Venture Management added most to Cymabay Therapeutics in Q3 2018, an estimated $448K increase.
  • Versant Venture Management's ten largest holdings make up 100% of its $294M portfolio in Q3 2018.
  • Versant Venture Management opened 1 new position and closed 0 in Q3 2018.
  • Versant Venture Management's portfolio value fell 8.3% quarter-over-quarter to $294M.

Based on Versant Venture Management's 13F filing for Q3 2018, filed 5 Oct 2018.